Effectiveness and Implementation of Mobile Health Platform for Medication Management and E-Labeling (eDrugSafe)
Launched by SEOUL NATIONAL UNIVERSITY · Nov 21, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The eDrugSafe trial is studying a mobile web platform designed to help adults who take multiple medications manage their medications better and improve their understanding of drug information. The main goal is to see if using this platform can help patients stick to their medication schedules, feel more confident in managing their health, and even reduce the number of hospital visits. The researchers will compare the use of eDrugSafe with traditional paper methods to determine if it is effective and easy to use in local pharmacies.
To participate in the study, you need to be between 18 and 79 years old, speak and understand Korean, and have a personal device like a smartphone or tablet that can access the internet. You should also be taking three or more medications, with at least one prescribed for a month or longer. If you decide to join, you’ll be assigned to either use the eDrugSafe platform or receive usual paper-based care for six months. Throughout the study, you’ll fill out surveys to help the researchers understand how well the platform is working and how feasible it is to use in community settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults aged 18 to 79 years.
- • 2. Individuals who can speak and understand Korean.
- • 3. Possession of a personal electronic device capable of accessing mobile applications and web services over wireless internet (bring participants' own device, BYOD).
- • 4. Patients taking three or more medications with at least one medication prescribed for 28 days or longer.
- • 5. Individuals who have provided direct consent to participate in the study.
- Exclusion Criteria:
- • 1. Individuals using any mobile web platform other than eDrugSafe for medication safety information purposes after enrollment.
- • 2. Individuals who do not consent to participate in the study or who withdraw their consent.
About Seoul National University
Seoul National University (SNU), a prestigious institution located in South Korea, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient outcomes. Renowned for its commitment to innovation and excellence, SNU collaborates with a diverse network of healthcare professionals and researchers to conduct rigorous studies across various fields of medicine. The university's robust infrastructure and emphasis on interdisciplinary collaboration enable the development of novel therapeutic strategies and the exploration of cutting-edge technologies, ultimately contributing to the global body of medical knowledge and enhancing healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, Gwanak Gu, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported